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df the Gram-positive food-grade bacterium, Lactococcus lactis. The first display format exploits an LPXTG-type anchoring motif of the
actococcal proteinase PrtP to covalently anchor MSA2 to the genetically modified producer cells. In a second display format, MSA2 was
used to the peptidoglycan-binding domain (Protein Anchor) of the lactococcal cell wall hydrolase AcmA and was non-covalently rebound
o the surface of non-genetically modified, non-living high-binder L. lactis cells, termed Gram-positive enhancer matrix (GEM) particles.
he L. lactis recombinants carrying covalently bound MSA2 were used to immunise rabbits through nasal and oral routes. The highest levels
f IgG antibodies reacting with near-native MSA2 on merozoites was elicited by oral administration. Intestinal antibodies to MSA2 were
roduced only after oral immunisation. MSA2-specific Th-cell activation could be demonstrated. Based on these results, the immunogenicity
n oral immunisations of MSA2, bound non-covalently to non-genetically modified L. lactis GEM particles, was compared with MSA2 that
as bound covalently to genetically modified L. lactis. These two forms elicited similar titres of serum antibodies. The results illustrate the
otential of using non-genetically modified L. lactis as a safe vaccine delivery vehicle to elicit systemic antibodies, thereby avoiding the
issemination of recombinant DNA into the environment.
2006 Elsevier Ltd. All rights reserved.
eywords: Surface display; Lactococcus lactis; Gram-positive enhancer matrix (GEM) particles; Plasmodium falciparum; Merozoite surface antigen 2 (MSA2);
ucosal vaccines
. Introduction
Nasal and oral vaccination is preferable to injections from
he point of view of safety, ease of administration and com-
liance. Mucosal vaccines are an alternative to injectable
accines, because it is e.g. increasingly more difficult to incor-
orate new injectable vaccines into the existing paediatric
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urangiy@hotmail.com (S. Yasawardena), a.zomer@rug.nl (A. Zomer),
.venema@rug.nl (G. Venema), j.kok@biol.rug.nl (J. Kok),
eenhouts@biomade.nl (K. Leenhouts).
vaccination programmes. In addition, mucosally delivered
vaccines activate the mucosal immune system to elicit pro-
tective secretory IgA antibodies and cellular immunity. This
is relevant for protection against viruses, bacteria and para-
sites that enter the body through mucosal surfaces and cause
diseases of the intestinal, respiratory and genital tracts.
Oral administration of soluble protein antigens generally
leads to systemic tolerance [1] but ingested particulate anti-
gens and microbes in some instances generate mucosal and
systemic immune responses [2] through stimulation of the
gut-associated lymphoreticular tissue (GALT). Both solu-
ble and particle-associated proteins given intranasally can,
through uptake by the nasopharynx-associated lymphoretic-
264-410X/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2006.02.040
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ular tissue (NALT), elicit local and distal mucosal as well
as systemic immune responses [3]. Therefore, oral or nasal
immunisation may also be useful against pathogens that
enter the body through routes other than mucosa. Attenu-
ated strains of bacterial pathogens such as Salmonella typhi,
Mycobacterium bovis and Bordetella pertussis are being
developed as vectors for mucosal immunisation, but suf-
fer from the disadvantage that they tend to disseminate in
the body [3] and can be unsafe in immuno-compromised
persons.
Lactococcus lactis is ubiquitous in the human environment
and in food. It is used for making cheese and buttermilk,
and is generally recognized as safe (GRAS). L. lactis sur-
vives passage through the gastrointestinal tract but does not
colonise the gut [4]. This lactic acid bacterium may there-
fore provide a safer alternative to attenuated pathogens for
mucosal immunisation purposes [5]. Several bacterial or
viral antigens have been expressed in L. lactis for use in
oral and intranasal immunisations [6–13]. The advantage in
relation to the potency of the elicited immune response of
anchoring the antigens to the cell wall of the producing L.
lactis cells as opposed to intracellular expression has been
demonstrated by others [9,10,12–14]. Therefore, we focused
in the present study on the cell wall presentation of the
antigen.






























tion against the clinical symptoms of malaria [21] and, in
some instances, inhibition of merozoite invasion of red blood
cells in vitro [22].
2. Materials and methods
2.1. L. lactis strains and growth conditions
L. lactis-NZ9000 and NZ9700 were grown in M17
medium (Difco, MD, USA) containing 1% glucose at 30 ◦C in
standing cultures. MSA2-recombinant L. lactis were grown
in the same medium with 5g ml−1 of chloramphenicol
for selection. MSA2-recombinant L. lactis were induced for
expression of MSA2 variants by adding the culture super-
natant of L. lactis-NZ9700, containing secreted nisin A, at a
1:1000 dilution and culturing overnight [23]. Overnight cul-
tures of a strain of L. lactis-NZ9000 lacking the cell wall
hydrolase AcmA (L. lactis-∆acmA) [24] were used to pre-
pare GEM particles as described before [17].
2.2. Cloning of MSA2 in L. lactis
The 819-nucleotide coding sequence of MSA2 [20] from
the 3D7 isolate of P. falciparum cloned in pBluescript IISK+






























[is in mucosal immunisation strategies, genetically modi-
ed vaccine strains were employed. Although L. lactis is
n innocuous bacterium, its widespread use as a genetically
odified strain in vaccinations, especially mucosal vaccina-
ions, may cause undesirable shedding of recombinant DNA
nto the environment with the attendant risk of transfer to
ther organisms. In order to eliminate this risk we developed a
on-genetically modified L. lactis support that allows highly
fficient binding of proteins that are fused to a lactococcal
eptidoglycan binding domain, the protein anchor (PA). For
his purpose, L. lactis cells are pre-treated with an acid that
emoves surface components [15], leaving non-living parti-
les that we termed Gram-positive enhancer matrix (GEM)
16,17]. The pre-treated and neutralized GEM particles are
sed to bind the antigen-PA fusion that was produced by
nother source (in trans binding). In this way, the antigen
an be presented to the immune system as a bacterial parti-
le that does not contain the recombinant DNA encoding the
ntigen.
We report here on the immunogenicity after oral deliv-
ry in rabbits of a Plasmodium falciparum parasite antigen
resented in two different ways on the surface of L. lactis;
i) covalently anchored to the peptidoglycan layer of the cell
all of live genetically modified L. lactis, using an anchoring
echanism based on the LPXTG motif from, in this case, the
actococcal proteinase PrtP (cP) [18] and (ii) non-covalently
ebound to non-genetically modified L. lactis GEM particles
sing the PA domain [15–17]. The P. falciparum protein used
as the 45 kDa merozoite surface antigen MSA2 [19,20],
ntibodies against which have been associated with protec-as PCR amplified from this plasmid and then cloned into
pNZ8048-based lactococcal vector for the expression of
SA2 under the control of the nisin A inducible promoter
nisA [23]. Plasmid pNG3041 (Fig. 1) expressed a 223-amino-
cid (aa) fragment of MSA2 (beginning with the sequence
NES and ending with AATS, GenBank accession num-
er A06129) lacking the MSA2 signal – and membrane-
nchoring sequences. Instead it had the signal – and pro-
equence [nucleotides 1206–1766 in Ref. [18]] of the lacto-
occal cell wall-associated proteinase PrtP at the N-terminus
or efficient secretion, together with a C-terminal anchor
equence (PA) derived from the L. lactis cell-wall hydro-
ase AcmA [corresponding to nucleotides 733–1488 in Ref.
24]]. The corresponding MSA2 fusion protein MSA2-PA
s termed MSA2-nCov for reasons of clarity. MSA2-nCov
s attached non-covalently to the cell wall of the producer
ells through the protein anchor [15], and is also secreted
nto the culture medium after which it can be rebound non-
ovalently to lactococcal GEM particles [15–17]. Plasmid
NG3043 (Fig. 1) expressed the same 223-aa fragment of
SA2 as in pNG3041, with the signal and pro-sequence
f PrtP at the N-terminus, but with a cell-wall spanning
nd covalent anchoring sequence of PrtP, cP, at its C-
erminus [corresponding to nucleotides 6539–6914 in Ref.
18]]. This MSA2 fusion protein MSA2-cP is termed MSA2-
ov. The plasmids pNZ8048 (negative control), pNG3041
nd pNG3043 were used to transform L. lactis-NZ9000,
hich has the nisRK genes in the chromosome needed for
he nisin-induced activation of PnisA [23], by electroporation
26].
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Fig. 1. Schematic drawings of the most relevant parts of pNG3041 and pNG3043. The indicated domains contain the nucleotide sequences encoding. Open
box: MSA2 without signal sequence and GPI anchor sequence. Black box: native signal sequence of MSA2. GPI anchor sequence of MSA2. The arrow
represents the nisin-inducible promoter of L. lactis. The lollypop represents a lactococcal transcriptional terminator sequence. signal sequence of PrtP.
prosequence of PrtP. one repeat of the AcmA cell wall anchor. The three repeats constitute the entire cell-wall anchor domain (PA). cell wall anchor
of PrtP (cP).
2.3. Quantiﬁcation of MSA2 expression
Coomassie blue staining after SDS-PAGE was performed
to quantitate the expression of MSA2 variants. Exponentially
growingL. lactis cells were induced for 4 h with a supernatant
containing nisin A and the cells were pelleted by centrifu-
gation, washed once in distilled water and resuspended in
buffer (20% sucrose, 10 mM Tris–HCl pH8.1, 10 mM EDTA
and 50 mM NaCl) containing 500g ml−1 lysosyme and
15 units ml−1 mutanolysin (Sigma, USA) and heated to 55 ◦C
for 15 min. Then 1 volume of 2× concentrated Laemmli sam-
ple buffer was added and the sample was heated to 100 ◦C for
3 min. MSA2-nCov, non-covalently bound to L. lactis GEM
particles, was extracted from GEMs with sample buffer at
100 ◦C. Ten microlitres of aliquots (5 × 108 cells) were anal-
ysed by SDS-PAGE (12% NuPage gels with MOPS buffer;
Invitrogen, USA) and stained with Coomassie R250(G) stain.
The intensity of the MSA2 bands was compared with BSA
standards analysed similarly by SDS-PAGE.
2.4. Immunoblotting, immunoﬂuorescence assay (IFA)
and immuno-electron microscopy
Ten microlitres of aliquots of L. lactis extracts, pre-















and photographed using a Zeiss microscope with incident UV
illumination and the Zeiss Axiovision digital imaging system
(Zeiss, Germany).
Immunogold electron microscopy was performed on
whole mount preparations of glutaraldehyde-fixed MSA2
surface-displaying L. lactis cells and GEM particles on
Formovar carbon-coated nickel grids. These were reacted
sequentially with rabbit anti-MSA2 and Auroprobe 15 nm
gold-labelled goat anti-rabbit IgG (Amersham, UK). Sam-
ples were then stained with 0.1% uranyl acetate and examined
using a Philips CM10 transmission electron microscope at
100 kV (Philips, The Netherlands).
2.5. Vaccine preparations
Stocks of L. lactis and L. lactis-pNG3043 for immunisa-
tion were prepared from overnight cultures (the latter strain
was induced overnight with nisin A for MSA2-Cov expres-
sion) and stored in aliquots of 1011 colony forming units (cfu)
per ml growth medium containing 10% glycerol at −80 ◦C.
The cells remain viable under these conditions and L. lactis-
pNG3043 retains MSA2-Cov on its surface, as demonstrated
by immunofluorescence assay (IFA).
Cultures of L. lactis-pNG3041 cells, induced for 4 h with












cere transferred to Hybond blotting membranes and probed
ith a 1:10,000 dilution of a rabbit antiserum to MSA2
aised against an MSA2-GST fusion protein [25]. The
lots were developed with 0.5g ml−1 alkaline-phosphatase-
abelled goat anti-rabbit IgG (H + L) antibodies followed by
BT/BCIP as a substrate.
For IFA, approximately 108 cells of pNG3043(MSA2-
ov), induced to express MSA2, or 108 L. lactis GEM parti-
les with bound MSA2-nCov, were washed in PBS (0.1 M
hosphate buffered saline, pH 7.2), and incubated with a
:500 dilution of the rabbit anti-MSA2 serum in PBS with 2%
SA for 2 h at 28 ◦C. After washing with PBS, the samples
ere incubated with 10g ml−1 Oregon green-conjugated
oat anti-rabbit IgG antibodies (Molecular Probes, USA)
iluted in PBS with 2% BSA for 1 h at 28 ◦C, and then viewedupernatant was collected and used as a source of secreted
SA2-nCov.L. lactisGEM particles were incubated with the
ell-free supernatant containing MSA2-nCov at a concentra-
ion of 2 × 108 GEM particles per ml at 37 ◦C for 15 min with
otary shaking at 150 rpm. The GEM particles were then col-
ected by centrifugation, washed twice in PBS and stored in
BS at −80 ◦C until further use at a concentration of 1011
articles per ml. L. lactis GEM particles retain MSA2-nCov
n the surface under these conditions, as demonstrated by
FA.
.6. Immunisations
New Zealand white rabbits obtained from the Medi-
al Research Institute, Colombo, Sri Lanka were used for
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Table 1
Serum antibody responses to immunisation through different routes with recombinant L. lactis-pNG3043 cells, which carry covalently bound MSA2-Cov
Route Immunogen 0 1st 2nd 3rd 3-II 4th Faecal Ab
i.m. L. lactis MSA2-Cov −ve −ve 2 4(3) 3 5 −ve
Nasal L. lactis −ve nd nd −ve nd nd nd
Nasal L. lactis −ve nd nd −ve nd nd nd
Nasal L. lactis MSA2-Cov −ve −ve 1 1(1) 1 1 nd
Nasal L. lactis MSA2-Cov −ve −ve −ve 1(1) 1 1 nd
Oral L. lactis −ve nd nd −ve nd nd −ve
Oral L. lactis −ve nd nd −ve nd nd −ve
Oral L. lactis MSA2-Cov −ve −ve 1 2(1) 1 2 +ve
Oral L. lactis MSA2-Cov −ve −ve 1 3(2) 1 3 +ve
Total serum antibody titres, determined by IFA at serial 10-fold dilutions, beginning at 1:10, after 0, 1, 2, 3 and 4 immunisations (0, 1st, 2nd, 3rd and 4th,
respectively) are expressed as the negative logarithms to the base ten. Absence of a detectable IFA reaction at 1:10 dilution of serum is indicated as −ve. The
numbers in parentheses in column 3rd are the corresponding titres of IgG antibodies determined by IFA with a specific anti-rabbit -chain antibody. 3-II is the
serum collected 15 weeks after the third immunisation. If antibody was detected by IFA in the undiluted faecal extract this is reported as +ve. nd: not done;
i.m.: intramuscular.
experimental immunisations in which the nasal and oral
routes of administration were explored with the L. lactis-
pNG3041(MSA2-Cov) vaccine. The care and use of ani-
mals were according to WHO guidelines (WHO/LAB/88.1).
The rabbits were ear-bled 7 days prior to immunisation to
obtain preimmune sera. Details of routes of immunisation and
immunogens are given in Table 1. Each group consisted of
two rabbits. As a positive control, L. lactis-pNG3041(MSA2-
Cov) was given intramuscularly (i.m.) to one rabbit. Prior
to immunisations, stocks of L. lactis (no MSA2 expression,
negative control) and L. lactis-pNG3041(MSA2-Cov) were
thawed, washed and resuspended in buffer at the appropriate
concentration for immunisations. Intramuscular injections
were performed with a total of 5 × 109 cfu in 100l PBS
into both rear hind legs. Nasal immunisation involved deliv-
ering a total of 1010 cfu in 100l PBS into the two nostrils
with a pipette. Prior to oral immunisation, the rabbits were
deprived of water and food for 6 h. They were then each fed
5 × 1010 cfu resuspended in 1 ml of 0.2N NaHCO3, 0.5%
glucose and 5% casein hydrolysate. This dose was repeated
for three successive days to obtain reproducible oral immu-
nisation. All immunisations were repeated twice at 3 weeks
intervals. Blood was collected 2 weeks after each immunisa-
tion to prepare sera termed bleeds 1st, 2nd and 3rd, respec-
tively. After three immunisations the rabbits were rested for












lines. The rabbits were ear-bled prior to immunisation to
obtain preimmune sera. Details of the immunisation and
immunogens are given in Table 2. Each group consisted
of two rabbits. Prior to immunisations, stocks of L. lactis-
pNG3041(MSA2-Cov) and L. lactis GEM particles with
bound MSA2-nCov were thawed, washed and resuspended
in 20% sucrose for oral immunisations. Prior to oral immuni-
sation, the rabbits were deprived of water and food for 2–4 h.
They were then each fed using a plastic disposable pipette tip
with 1 ml containing 5 × 1010 cfu L. lactis-pNG3041(MSA2-
Cov) or 5 × 1010 GEM particles with bound MSA2-nCov.
Each dose was repeated for three successive days to obtain
reproducible oral immunisation. Altogether, three oral immu-
nisations were given at 3 weeks intervals. Rabbits were
ear-bled 2 weeks after each immunisation to obtain sera
for antibody assays. The sera were stored at −20 ◦C until
use.
All vaccines were administered without additional adju-
vants. Adverse effects consequent to the immunisations were
not observed indicating that live recombinant L. lactis as well
















dest the decrease in antibody titres. The rabbits were given a
ourth and final immunisation 16 weeks after the third immu-
isation, and serum collected 2 weeks later (termed 4th), to
onfirm boosting of immunity. The fourth oral immunisation,
owever, consisted of two, and not three, successive days of
eeding 5 × 1010 cfu. Collected sera were stored at −20 ◦C
ntil use.
New Zealand white rabbits obtained from Harlan laborato-
ies, The Netherlands, were used for immunisations in which
he L. lactis GEM particles carrying MSA2-nCov and the L.
actis-pNG3041(MSA2-Cov) vaccines were compared. The
are and use of animals were according to institutional guide-erum antibody responses after oral immunisation with recombinant L.
actis-pNG3043 carrying covalently bound MSA2-Cov or L. lactis GEM
articles containing non-covalently bound MSA-nCov
mmunogen 0 2nd 3rd 3rd IgG
. lactis MSA2-Cov −ve 3 4 4
. lactis MSA2-Cov −ve 2 4 4
. lactis GEM MSA2-nCov −ve 2 4 4
. lactis GEM MSA2-nCov −ve 2 4 4
itres determined by IFA at serial 10-fold dilutions, beginning at 1:10, are
xpressed as the negative logarithms to the base ten. No detectable reaction
t a 1:10 dilution of the serum is shown as −ve; 0, 2nd and 3rd refer to preim-
une serum and serum obtained after 2 and 3 immunisations, respectively;
rd IgG is the IgG antibody titre in the serum after three immunisations, as
etermined with a rabbit  chain-specific secondary antibody.
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2.7. Detection and measurement of serum antibody
response
The detection of typical bunch of grape-like patterns of
fluorescence on segmented schizonts of 3D7 P. falciparum is
based on antibody recognition of near-native MSA2 on the
surface of the malaria parasite [19]. This method was used
to determine the MSA2 antibody titre in the sera of immu-
nised rabbits. IFA was performed on acetone–methanol fixed
late-stage 3D7 parasites as previously described [19]. Ten-
fold serial dilutions of the antisera in 2% BSA were used
in IFA to determine the titre. The greatest dilution of serum
giving a discernible bunch of grapes pattern on late schizonts
was taken as the titre. For detection of all antibody isotypes,
FITC-conjugated sheep anti-rabbit Ig (Silenius, Australia)
or Oregon Green-conjugated goat anti-rabbit Ig with H + L
specificity (Molecular Probes, USA), was used as secondary
antibody. For detection of IgG antibodies only, a FITC-
conjugated mouse monoclonal antibody RG-96, with speci-
ficity against rabbit  chains (Sigma, USA), or a fluorescein-
conjugated, affinity-purified, rabbit antibody with specificity
against rabbit  chains (Rockland, USA), was used instead.
A total cell extract of L. lactis NZ9000 was used as target










conjugated sheep anti-rabbit Ig (Silenius, Australia) was used
as the secondary antibody.
3. Results
3.1. Expression of MSA2
The expression formats of MSA2 are schematically drawn
in Fig. 1. Expression of the MSA2 fusion proteins was anal-
ysed in Coomassie-stained gels and in Western blots. An
example of such gels and blots is given in Fig. 2. MSA2-Cov
was present as a 70-kilo Dalton (kDa) protein in the total
cell extract of L. lactis-pNG3043 (Fig. 2, lane 2). MSA2-
nCov was secreted by L. lactis-pNG3041 as a 65 kDa protein
(Fig. 2, lane 4). The secreted MSA2-nCov was bound to L.
lactis GEM particles (Fig. 2, lane 6). By comparative protein
gel electrophoresis experiments using BSA protein standards
we estimated that L. lactis produced approximately 800 ng
MSA2-Cov per 5 × 108 cells. The same number of GEM
particles contained about 600 ng of MSA2-nCov (data not
shown). This corresponds to approximately 1.4 × 104 MSA2-
Cov molecules per cell for L. lactis-pNG3043 and about 104
MSA2-nCov molecules per GEM particle.














d on prote.8. Faecal antibody responses
Fresh faecal pellets were collected from the rabbits 2
eeks after the third immunisation and stored at −20 ◦C
ntil required. One millilitre of PBS containing 1% BSA and
mM phenylmethyl suphonyl fluoride was then added per
00 mg of faeces and incubated overnight at 4 ◦C. The sam-
le was vortexed to disrupt all solid material and centrifuged
t 16,000 × g for 5 min. The supernatant containing extracted
ntibody was stored at −20 ◦C until testing by IFA. FITC-
ig. 2. Panel A: SDS-PAGE analysis of Coomassie-stained proteins in cell
ector; lane 2: L. lactis-pNG3043(MSA2-Cov); lane 3: the equivalent of 1 m
upernatant of L. lactis-pNG3041(MSA2-nCov); lane 5: L. lactis GEM pa
. lactis-pNG3041(MSA2-nCov) cell-free culture supernatant. M: molecul
re indicated in kDa in the left margin. The asterisk and the arrow indicate
ecorated with anti MSA2-GST antibodies to detect MSA2-containing fusiarticles
The surface localization of MSA2-Cov on L. lactis-
NG3043 cells and of MSA2-nCov on GEM particles was
onfirmed by immunofluorescence with rabbit anti-MSA2
erum (Fig. 3) and by immuno-electron microscopy (Fig. 4).
he microscopic observations suggest that surface-exposed
SA2-Cov is mainly found in the region of the newly form-
ng septum in dividing cells and at the poles of the L. lactis-
NG3043 cells. MSA2-nCov was more evenly distributed on
(5 × 108 cells) prepared from—lane 1: L. lactis-pNZ8048, empty cloning
re supernatant of L. lactis-pNZ8048; lane 4: the equivalent of 1 ml culture
lane 6: L. lactis GEM particles with MSA2-nCov absorbed from 1.25 ml
ht marker (precision Plus Prestained Marker, BioRad), the sizes of which
itions of MSA2-Cov and MSA2-nCov, respectively. Panel B: Immunoblot
ins. Content of the lanes is the same as in panel A.
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Fig. 3. Immunofluorescence assay (IFA) showing reaction of rabbit anti-
MSA2 antibodies on: (A) L. lactis-pNG3043 induced for 4 h with nisin
to express MSA2-Cov; (B) L. lactis GEM particles after absorption with
MSA2-nCov from the cell-free culture supernatant of L. lactis-pNG3041
induced for 4 h to express MSA2-nCov. The negative controls did not show
any fluorescence (data not shown).
L. lactis GEM particles (Figs. 3 and 4). In any case, similar
levels of MSA2 seem to be surface displayed by these two
presentation formats.
The most efficient mucosal route for the delivery of MSA2
was first determined using the live recombinant L. lactis anti-
gen surface display system, i.e. L. lactis-pNG3043(MSA2-
Cov).
3.3. Immunogenicity of MSA2-Cov delivered by mucosal
routes
New Zealand white rabbits were used to examine the
oral and nasal routes of immunization. The immunisa-
tions, including two boosters, with recombinant L. lactis-
pNG3043(MSA2-Cov) delivered, per rabbit, a total of 48 and
720g of MSA2-Cov protein after nasal and oral immunisa-
tions, respectively. One rabbit obtained three intramuscular
(i.m.) immunisations with L. lactis(MSA2-Cov) as a posi-
tive control (totally 24g MSA2-Cov). Immunofluorescence
reactivity against the surface of P. falciparum merozoites was
used to assay antibodies in sera and faecal extracts, as this
measures antibodies reacting with near-native MSA2 protein
(see Section 2). The IFA results of the immunised rabbits
are summarised in Table 1. A single immunisation with L.
lactis(MSA2-Cov) administered i.m., nasally or orally did











Fig. 4. Electron micrographs showing, by immunogold labelling using rabbit ant
surface of: (A) L. lactis(MSA2-Cov), 20 min after induction with nisin A; (B) L. l
size of 1m. For detection, secondary antibodies labelled with 15 nm gold particle
preparation procedure (see Section 2), the GEM particles shrink and the photograpfurther boosting immunisation was needed in all cases
o detect antibodies. It is apparent that the positive control,
.m. immunisation with L. lactis(MSA2-Cov), led to good
erum antibody titres. The titres waned 15 weeks after the
hird injection but could be boosted to the original levels by
fourth i.m. injection. Levels of IgG antibodies after three
mmunisations, as measured with an FITC-conjugated mouse
onoclonal antibody against rabbit  chains, were one order
f magnitude less but still indicate that IgG antibodies con-
titute the major portion of the antibody response against
i-MSA2 antiserum and gold-labelled goat anti-rabbit IgG, MSA2 on the
actis GEM particles with attached MSA2-nCov. The black bars indicate a
s were used, both in (A) and (B). Because of the used whole mount sample
h was more enlarged in order to obtain similar sized bacterial particles.
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Fig. 5. Immunoblots showing reaction of sera of immunised rabbits with total protein extracts of 5 × 108 L. lactis cells per lane—lane 0: preimmune serum;
lane 2: serum after the 2nd immunisation; lane 3: serum after the 3rd immunisation. Serum dilution 1:100. Panel A: Serum of a rabbit immunised i.m. with L.
lactis(MSA2-Cov). Panel B: Serum of a rabbit orally immunised with L. lactis(MSA2-Cov). Panel C: Serum of a rabbit orally immunised with L. lactis GEM
particles with bound MSA2-nCov.
MSA2-Cov expressed on cells of L. lactis-pNG3043(MSA2-
Cov) after i.m. immunisation.
Intranasal immunisation with L. lactis(MSA2-Cov)
elicited low titres (10−1) of antibodies after three immu-
nisations. The oral immunisation procedure led to higher
antibody titres (10−2 to 10−3) than did the intranasal immuni-
sation. Antibody levels decreased significantly by 15 weeks
but could be boosted to original levels by a subsequent (4th)
oral immunisation. The results with the anti-rabbit -chain
antibody and the boosting suggest that much of the antibody
present in the serum after oral immunisation is IgG.
MSA2-specific antibodies were detectable in undiluted
extracts of faecal pellets after oral immunisation, but not after
i.m. immunisation with L. lactis(MSA2-Cov).
3.4. Immunogenicity of MSA2-Cov and MSA2-nCov
after oral immunisation
Based on the results obtained for MSA2-Cov, we con-
cluded that the preferred route for mucosal delivery in rab-
bits of the MSA2 antigen by live recombinant L. lactis is
oral administration. We next determined the capability of
non-living non-genetically modified lactococcal GEM par-
ticles carrying non-covalently bound MSA2-nCov to elicit









body titres increased after a third immunisation (10−4), in
all instances. The antibodies were predominantly of the IgG
subclass in all cases.
3.5. Anti-carrier response
The immune response to the carrier may be of influence on
the safety of the delivery system in humans. Also the deliv-
ery route may be of influence on the anti-carrier response.
As a first exploration of this issue we examined the anti-
carrier antibody response in more detail in immunoblots in
which a total lysate of L. lactis cells was used as a target
for serum from rabbits immunised with the different MSA2
presentation formats (Fig. 5). The staining bands in the lanes
indicate that L. lactis proteins present at that position in the
SDS-PAA gel reacted with the indicated rabbit antiserum.
A pronounced anti-L. lactis protein response was observed
after 2 or 3 i.m. administrations of the live recombinant L.
lactis vaccine (Fig. 5A). This response was clearly reduced
after oral delivery of the vaccine (Fig. 5B). The anti-L. lactis
response was even more minimized in the rabbit orally immu-
nised with the GEM particle vaccine (Fig. 5C). It is clear from
these results that mucosal delivery reduces the anti-carrier
response and that the L. lactis GEM particles generate less




vion. A comparison was made with L. lactis(MSA2-Cov).
. lactis(MSA2-Cov) delivered a total of 720g MSA2-Cov
hile GEM particles delivered 540g of MSA2-nCov after
hree immunisations. The rabbit anti-MSA2 serum antibody
esponses to the immunisations were characterised by IFA
nd are summarised in Table 2. The results show that specific
ntibodies against near-native MSA2 were detectable after
wo immunisations (titres of 10−2 to 10−3), and that anti-actis cells.
. Discussion
We investigated the immunogenicity of the putative pro-
ective MSA2 antigen of P. falciparum merozoites in mucosal
accines. It was also our aim to evaluate the feasibility of a
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novel bacterial antigen display system that avoids the use of
recombinant DNA in the vaccine. For this purpose, we com-
pared MSA2 vaccines based on a live recombinant L. lactis
surface display system that exploits the commonly used cova-
lent LPXTG-type anchoring cassette [9,10,12–14,27,28],
with a non-living non-genetically modified L. lactis surface
display system, the GEM particles. The GEM particles can be
loaded with the antigen when the latter is fused to the non-
covalent cell wall binding domain (PA) of the lactococcal
protein AcmA. Others have already demonstrated that non-
living recombinant lactococci are as efficient as live L. lactis
cells in eliciting antibody responses in mucosal immuniza-
tions [7]. The AcmA cell wall binding domain PA has been
used to display antigens on live recombinant [27,28] or non-
recombinant live L. lactis cells [29]. Here we used acid pre-
treated L. lactis cells, which we termed GEM particles [16],
for antigen delivery because this pre-treatment enhances the
binding capacity for PA fusion proteins [15–17]. Moreover,
the use of GEM particles in vaccines prevents the dissemina-
tion of recombinant DNA in the environment. The results of
the oral immunisations confirm that non-living L. lactis GEM
particles are equally efficient in eliciting antigen-specific
antibody responses as living L. lactis cells. Consequently, the
present results show that L. lactis GEM particles, which con-
sist of peptidoglycan largely devoid of lipotechoic acid and






























ings suggest that foreign proteins expressed in L. lactis can
also be used in oral vaccination procedures to elicit protective
secretory antibodies in the gut.
Antibody titres achieved by using both L. lactis display
formats of MSA2 are better than those achieved by immuni-
sation with plasmid DNA [34] or peptide-diphtheria toxoid
conjugates [35] through the intramuscular and intradermal
routes. Intramuscular immunisation with synthetic peptide
polymers based on MSA2 B-cell epitopes elicited high-titre
antibodies against the immunising peptide, which reacted
only poorly with near-native MSA2 on merozoites [36].
While very high titres (10−6) of antibodies reacting with
near-native MSA2 is achievable in animals with recombinant
MSA2 in intramuscular immunisations, this required the use
of Freund’s adjuvant, which is not acceptable for human use
[25]. Adjuvants with fewer side effects that have been tried on
humans with recombinant MSA2, have yielded poorer anti-
body titres [37]. Therefore oral immunisation with L. lactis
MSA2 display formats is a promising method of generating
systemic anti-MSA2 antibodies in man for protection against
malaria.
The use of heterologous proteins anchored through the
PA to non-genetically modified L. lactis GEM particles is as
effective as the use of living recombinant L. lactis cells for
eliciting systemic IgG antibodies against the protein of inter-

















Rlso efficiently stimulate antigen presenting cells without the
se of additional adjuvants. In addition, GEM particles elicit
ess anti-carrier response than live L. lactis cells. Not requir-
ng additional adjuvant and a minimal anti-carrier response
ould be desirable characteristics for any vaccine to be used
n human vaccinations. Further investigations are warranted
o reveal the mechanism of immune stimulation.
Our results with the recombinant L. lactis delivery system
uggest that oral immunisation leads to higher levels of serum
ntibodies than the corresponding nasal immunisation proce-
ure employed. A similar observation was made by Pei et al.
13] in immunisations with L. lactis expressing the SARS-
oronavirus nucleocapsid protein. Also other investigators
bserved significant systemic immune responses after oral
mmunisations with recombinant lactococci [7–10] and in
ome cases protection against a lethal challenge was obtained
7,10,11]. Protection against infection with P. falciparum can
ot be evaluated in a challenge model using non-primate
nimals. The anti-MSA2 serum antibodies generated in the
resent study in the oral immunisations with both delivery
ormats, react with near-native antigen on merozoites, as evi-
enced by the IFA studies on intact merozoites. Reaction
f the antibodies with merozoite surfaces is related to their
iological efficacy, i.e. the inhibition of red cell invasion.
n addition, the demonstration of systemic IgG antibodies
hose levels can be boosted implies that MSA2-specific Th
ells are activated through mucosal immunisation. The detec-
ion of MSA2-specific IgA antibodies in the extracts from
aecal pellets of rabbits immunised orally is consistent with
he observation of others [7,10,11,32,33]. Therefore, the find-t avoids the need for introducing recombinant cells or addi-
ional adjuvants into vaccine recipients; (ii) it elicits a weaker
mmune response against the vector, thereby increasing safety
nd possibly permitting a greater number of immunisations
han feasible with intact L. lactis; (iii) the process more easily
ermits immunisation with different combinations of anti-
ens on the same particle [16]. Experiments are presently in
rogress to determine whether proteins absorbed on the GEM
articles are able to induce antigen-specific systemic Tc cells,
hich could further widen the use of the GEM particles in
accine preparations.
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